Search Results
Event
The Advances in Genomic Technology Development (AGTD) 2023 Annual Meeting was hosted by the Technology Development Coordinating Center (TDCC) in-person and virtually from Tuesday, June 6, until Thursday, June 8, at The Sanford Consortium for Regenerative Medicine, La Jolla, CA.
… San Diego 10:30 a.m. Fernando Aleman, Ph.D., Navega Therapeutics Aaron Parker, Ph.D., J.D., Bristol Myers Squibb … Gonzales, Ph.D., Goodwin Katannya Kapeli, Ph.D., Trotana Therapeutics aclyn Einstein, Ph.D., Trotana Therapeutics Sergio Duron Ph.D., Enlaza Therapeutics Adam …
Staff
Antwi-Boasiako Oteng is a Research Fellow at the Center for Research on Genomics and Global Health.
News Release
The U.S. Food and Drug Administration has approved the first treatment for progeria, a rare and fatal pediatric disease, characterized by dramatic, rapid aging beginning in childhood.
News Release
NIH researchers identified a novel role for a gene known as heat shock protein 60, finding it is critical in tissue regeneration and wound healing.
… their colleagues, may help in the development of effective therapeutics for accelerating wound closure in diabetic …
News Release
NIH investigators have discovered that genomic switches of a blood cell are key to regulating the human immune system.
Staff
Abdel Elkahloun is an associate investigator in NHGRI's Office of Scientific Core Facilities.
Staff
Dr. Introne is a pediatrician, clinical and biochemical geneticist in the Medical Genetics Branch in NHGRI.
For Patients and Families
Por lo general, se considera que una enfermedad es rara cuando afecta a menos de 200,000 personas en los Estados Unidos en cualquier momento dado.
… de Tratamientos para enfermedades raras y desatendidas ( Therapeutics for Rare and Neglected Diseases , TRND), a fin …
Research Funding
The Knockout Mouse Phenotyping Project (KOMP2) collaborates with the International Mouse Phenotyping Consortium (IMPC) to knockout and characterize all protein-coding genes in the mouse genome.
Event
A joint NHGRI-NCATS hosted meeting bringing together researchers, clinicians, families and patient advocates from around the world to discuss the natural history, disease pathophysiology, genetics and treatments for rare inborn metabolic errors.
… 3 Elizabeth Ottinger, Ph.D. Head of Project Management, Therapeutics Development Branch, NCATS 2:30 - 2:50 p.m. …